Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Hodgkin Disease × Prednisone × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

OTHER 23 NETWORK 9 NIH 7 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Prostatic Neoplasms 81 Lymphoma, Large B-Cell, Diffuse 26 Neoplasms 18 Lymphoma, Follicular 18 Lymphoma, Non-Hodgkin 17 Multiple Myeloma 15 Lymphoma 15 Neoplasm Metastasis 10 Lymphoma, B-Cell 10 Lymphoma, T-Cell, Peripheral 7 Recurrence 6 Prostatic Neoplasms, Castration-Resistant 5 Prostate Cancer Metastatic 5 Metastatic Castration-resistant Prostate Cancer 5 Lymphoma, Mantle-Cell 5 Lymphoma, B-Cell, Marginal Zone 4 Hematologic Diseases 4 Parkinson Disease 4, Autosomal Dominant Lewy Body 3 Ovarian Neoplasms 3 Metastatic Castration-Resistant Prostate Cancer 3 Leukemia, Lymphocytic, Chronic, B-Cell 3 Metastatic Castration Resistant Prostate Cancer 2 Lymphoma, T-Cell 2 Lymphoma, Large-Cell, Anaplastic 2 Leukemia 2 Graft vs Host Disease 2 Endometrial Neoplasms 2 Colorectal Neoplasms 2 Castrate-Resistant Prostate Cancer 2 Carcinoma, Non-Small-Cell Lung 2

Interventions

Brentuximab Vedotin 20 pembrolizumab 11 Vinblastine 6 Doxorubicin 6 Dacarbazine 6 plerixafor 4 fludarabine 4 Nivolumab 4 Cyclophosphamide 4 Azacitidine 4 Melphalan 3 Granulocyte Colony-Stimulating Factor 3 Gemcitabine 3 Filgrastim 3 Etoposide 3 Busulfan 3 Bleomycin 3 pegfilgrastim 2 mocetinostat 2 givinostat hydrochloride 2 givinostat 2 fludarabine phosphate 2 cc-486 2 abexinostat 2 TPI-287 2 Panobinostat 2 Mycophenolic Acid 2 Leukapheresis 2 Clofarabine 2 Carmustine 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03407144 2026-02-19

MK-3475-667

Merck Sharp & Dohme LLC

Phase 2 Active not recruiting

Hodgkin Disease

Data powered by HemOnc (CC BY 4.0) Colophon ⚡